HEMISPHERIAN AS

Facts

Source: Firmafakta, with business data from public registers.

organisasjonsnummer:

925333409

navn:

HEMISPHERIAN AS

organisasjonsform:

kode:

AS

beskrivelse:

Aksjeselskap

naeringskode1:

kode:

72.100

beskrivelse:

Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk

antallAnsatte:

5

hjemmeside:

not reported by source

epostadresse:

not reported by source

telefon:

not reported by source

forretningsadresse:

adresse:

Lørenveien 73A

poststed:

OSLO

postnummer:

0585

kommune:

OSLO

stiftelsesdato:

2020-06-15

registreringsdatoenhetsregisteret:

2020-07-13

aktivitet:

Forskning og utvikling av legemidler, konsulenttjenester innenfor, software og beregningsbiologi.

vedtektsfestetFormaal:

Forskning og utvikling av legemidler, konsulenttjenester innenfor, software og beregningsbiologi, selv eller gjennom investeringer og, eierskap i andre selskaper.

View the address in Geonorge

Board and other roles

Source: Firmafakta. Also see the separate Brønnøysund lookup under related lookups.

Daglig leder

• Daglig leder: Zeno Albisser

Regnskapsfører

• Regnskapsfører: COMPLÉR ACCOUNTING AS

Revisor

• Revisor: BHL AS

Styre

• Styremedlem: Dallas Christian Hack
• Styremedlem: Frode Vartdal
• Styremedlem: Wolfram Thomas Eichner
• Styrets leder: Paul Govert Michael Lelieveld

Owners

Source: Firmafakta shareholder dataset.

1. KISTEFOS AS – 16.48 % (5623 shares, share class: Ordinære aksjer)
2. MENELDOR AT COPERATIE III U.A – 14.34 % (4891 shares, share class: Ordinære aksjer)
3. MENELDOR NHS COOPERATIE I U.A – 13.44 % (4585 shares, share class: Ordinære aksjer)
4. ALBISSER AS – 8.65 % (2951 shares, share class: Ordinære aksjer)
5. JANDA AS – 8.65 % (2951 shares, share class: Ordinære aksjer)
6. PRIKRYLOVA AS – 4.86 % (1658 shares, share class: Ordinære aksjer)
7. PAACS INVEST AS – 4.29 % (1462 shares, share class: Ordinære aksjer)
8. GILBERT GERBER – 3.73 % (1272 shares, share class: Ordinære aksjer)
9. INVESTINOR INDIREKTE II AS – 3.73 % (1272 shares, share class: Ordinære aksjer)
10. NECTERA AS – 2.11 % (720 shares, share class: Ordinære aksjer)
11. LEE W BERRYMAN – 1.95 % (664 shares, share class: Ordinære aksjer)
12. KVANTIA AS – 1.76 % (602 shares, share class: Ordinære aksjer)
13. LIVERMORE INVEST AS – 1.59 % (541 shares, share class: Ordinære aksjer)
14. OJT HOLDING AS – 1.59 % (541 shares, share class: Ordinære aksjer)
15. STORSTAD AS – 1.59 % (541 shares, share class: Ordinære aksjer)
16. MARK ROBERTSON – 1.29 % (441 shares, share class: Ordinære aksjer)
17. LIE HOLDING AS – 1.26 % (431 shares, share class: Ordinære aksjer)
18. STRIGEN AS – 1.15 % (394 shares, share class: Ordinære aksjer)
19. ACIER AS – 1.11 % (378 shares, share class: Ordinære aksjer)
20. STOKO AS – 1.03 % (350 shares, share class: Ordinære aksjer)
21. HAUKELI INVEST AS – 0.95 % (323 shares, share class: Ordinære aksjer)
22. LISE AS – 0.95 % (323 shares, share class: Ordinære aksjer)
23. PORVENIR AS – 0.95 % (323 shares, share class: Ordinære aksjer)
24. EAO INVEST AS – 0.7 % (238 shares, share class: Ordinære aksjer)
25. CS3 HOLDING AS – 0.37 % (127 shares, share class: Ordinære aksjer)
26. FRODE VARTDAL – 0.31 % (107 shares, share class: Ordinære aksjer)
27. JAN EILER FLEISCHER – 0.31 % (107 shares, share class: Ordinære aksjer)
28. JERNIMPORT AS – 0.31 % (107 shares, share class: Ordinære aksjer)
29. JGB MANAGEMENT AS – 0.31 % (107 shares, share class: Ordinære aksjer)
30. VESTLAND HOLDING AS – 0.13 % (43 shares, share class: Ordinære aksjer)
31. CAABY AS – 0.06 % (21 shares, share class: Ordinære aksjer)
32. FINYIELD AS – 0.06 % (21 shares, share class: Ordinære aksjer)

Fetch a longer owner list

Company holdings

No holdings found.

Grants and support

Sources provided through Firmafakta: Innovation Norway, the EU, the Research Council of Norway and SkatteFUNN.

Innovasjon Norge (0)

No registered grants.

EU-tildelinger (0)

No registered grants.

Forskningsrådet (3)

3 results

1. id:

   76925

   prosjektnummer:

   346333

   prosjekttittel:

   GLIXOV: GLIX5 for Ovarian Cancer

   prosjektstart:

   2024

   prosjektslutt:

   2025

   prosjektansvarlig_navn:

   HEMISPHERIAN AS

   organisasjonsnummer:

   925333409

   sokt_belop:

   Onkologi

   tildelt_belop:

   0.0

   virkemiddel:

   Programmer

   aktivitet:

   Brukerstyrte innovasjonsprogrammer

2. id:

   73834

   prosjektnummer:

   338453

   prosjekttittel:

   A one-of-a-kind approach to treat Ovarian Cancer

   prosjektstart:

   2023

   prosjektslutt:

   2024

   prosjektansvarlig_navn:

   HEMISPHERIAN AS

   organisasjonsnummer:

   925333409

   sokt_belop:

   Onkologi

   tildelt_belop:

   0.0

   virkemiddel:

   Felleskostnader

   aktivitet:

   Utlysningsaktiviteter

3. id:

   63179

   prosjektnummer:

   317661

   prosjekttittel:

   GLIX1 - A new drug to treat glioblastoma multiforme (GBM)

   prosjektstart:

   2021

   prosjektslutt:

   2023

   prosjektansvarlig_navn:

   HEMISPHERIAN AS

   organisasjonsnummer:

   925333409

   sokt_belop:

   Onkologi

   tildelt_belop:

   0.0

   virkemiddel:

   Programmer

   aktivitet:

   Brukerstyrte innovasjonsprogrammer

SkatteFUNN (3)

3 results

1. id:

   71118

   innsendt_dato:

   2024-08-28

   prosjektnummer:

   1815

   bedriftsnavn:

   HEMISPHERIAN AS

   prosjekttittel:

   GLIXOV: GLIX5 for Eggstokkreft_Skattefunn_2024

   organisasjonsnummer:

   925333409

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   not reported by source

   soknad_godkjent:

   not reported by source

   soknad_avslatt:

   not reported by source

   vedtaksdato:

   na

   prosjekt_fra_ar:

   2024

   prosjekt_til_ar:

   2025

   sammendrag:

   Cancer is the second-leading cause of death globally, posing a major health crisis. Current therapies benefit only a small fraction of cancer patients, leading to significant healthcare costs on ineffective treatments. Ovarian cancer (OC) remains largely incurable, with only modest survival improvements, highlighting the urgent need for new strategies. Hemispherian’s novel drug, GLIX5, targets an unrecognized DNA pathway with exceptional anti-tumor efficacy. Co-developed with a sensitivity predictive biomarker (SPB), GLIX5 offers a personalized treatment approach. It has shown promising efficacy across various cancers, suggesting broader potential. Our project advances GLIX5’s preclinical development, explores other indications through an SPB-driven strategy, and establishes a scalable, cost-efficient CMC process. This aims to deliver smarter, targeted interventions, reducing unnecessary costs and offering OC patients more time with loved ones.

2. id:

   69262

   innsendt_dato:

   2023-09-01

   prosjektnummer:

   349005

   bedriftsnavn:

   HEMISPHERIAN AS

   prosjekttittel:

   GLIX1 therapeutics for the treatment of Glioblastoma

   organisasjonsnummer:

   925333409

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2023-12-14

   prosjekt_fra_ar:

   2023

   prosjekt_til_ar:

   2025

   sammendrag:

   Glioblastoma multiforme, a high-grade glioma, is the most prevalent and aggressive malignant tumor of the central nervous system. Glioblastoma multiforme is the leading cause of death by disease in children. With the currently available treatment, the median overall survival of glioblastoma patients is 13.9 months with 2-year survival of 22.5% and 5-year survival of 5.3%. Compounding the poor patient survival rates, currently available treatments often cause debilitating side-effects, resulting in poor quality of life. This poor patient survival rate and horrendous end-of-life quality highlights an urgent need to identify novel strategies to target glioblastoma multiforme. As recent reports and key opinion leaders suggest, glioblastoma multiforme is a disorder with one of the highest unmet needs in oncology. In partnership with world class eurosurgeons and medicinal chemists we aim to develop pharmaceuticals that we have discovered to treat glioblastoma multiforme patients. Hemispherian scientists have identified and are advancing two compounds that are highly effective in treating these deadly brain tumors.

3. id:

   65303

   innsendt_dato:

   2022-08-25

   prosjektnummer:

   339253

   bedriftsnavn:

   HEMISPHERIAN AS

   prosjekttittel:

   New Therapeutics for the most aggressive tumor of the central nervous system

   organisasjonsnummer:

   925333409

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2022-11-24

   prosjekt_fra_ar:

   2022

   prosjekt_til_ar:

   2024

   sammendrag:

   Glioblastoma multiforme, a high-grade glioma, is the most prevalent and aggressive malignant tumor of the central nervous system. Glioblastoma multiforme is the leading cause of death by disease in children. With the currently available treatment, the median overall survival of glioblastoma patients is 13.9 months with 2-year survival of 22.5% and 5-year survival of 5.3%. Compounding the poor patient survival rates, currently available treatments often cause debilitating side-effects, resulting in poor quality of life. This poor patient survival rate and horrendous end-of-life quality highlights an urgent need to identify novel strategies to target glioblastoma multiforme. As recent reports and key opinion leaders suggest, glioblastoma multiforme is a disorder with one of the highest unmet needs in oncology. In partnership with world class eurosurgeons and medicinal chemists we aim to develop pharmaceuticals that we have discovered to treat glioblastoma multiforme patients. Hemispherian scientists have identified and are advancing two compounds that are highly effective in treating these deadly brain tumors.

Subunits

• HEMISPHERIAN AS (925363502)

Open positions

count:

0

stillinger:

No results.

Related lookups

• Doffin notices where HEMISPHERIAN AS is the buyer
• Search broadly for HEMISPHERIAN AS in Doffin
• Open positions related to HEMISPHERIAN AS
• Latest financial statement
• Patents and trademarks
• Official entity information from the Brønnøysund Register Centre
• Official roles from the Brønnøysund Register Centre
• Corporate group structure from the Brønnøysund Register Centre